                         SEQUENCE LISTING

<110>  DUKE UNIVERSITY
 
<120>  POLYMER CONJUGATES HAVING REDUCED ANTIGENICITY AND METHODS OF 
       USING THE SAME

<130>  028193-9235-WO00

<140>  PCT/US2016/068141
<141>  2016-12-21

<150>  62/407,403
<151>  2016-10-12

<150>  62/329,800
<151>  2016-04-29

<150>  62/310,534
<151>  2016-03-18

<150>  62/270,401
<151>  2015-12-21

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  5
<212>  PRT
<213>  Sortase A recognition site, polypeptide


<220>
<221>  X
<222>  (3)..(3)
<223>  any amino acid

<400>  1

Leu Pro Xaa Thr Gly 
1               5   


<210>  2
<211>  5
<212>  PRT
<213>  Sortase A recognition site, polypeptide

<400>  2

Leu Pro Glu Thr Gly 
1               5   


<210>  3
<211>  5
<212>  PRT
<213>  Sortase A recognition site, polypeptide


<220>
<221>  X
<222>  (3)..(3)
<223>  any amino acid independent of X located at position 4

<220>
<221>  X
<222>  (4)..(4)
<223>  any amino acid independent of X located at position 3

<400>  3

Leu Pro Xaa Xaa Gly 
1               5   


<210>  4
<211>  3
<212>  PRT
<213>  Linker, polypeptide

<400>  4

Gly Gly Cys 
1           


<210>  5
<211>  24
<212>  PRT
<213>  Linker, polypeptide

<400>  5

Gly Gly Cys Gly Gly Cys Gly Gly Cys Gly Gly Cys Gly Gly Cys Gly 
1               5                   10                  15      


Gly Cys Gly Gly Cys Gly Gly Cys 
            20                  


<210>  6
<211>  15
<212>  PRT
<213>  Linker, polypeptide

<400>  6

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
1               5                   10                  15  


<210>  7
<211>  80
<212>  PRT
<213>  Linker, polypeptide


<220>
<221>  X
<222>  (4)..(4)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (9)..(9)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (14)..(14)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (19)..(19)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (24)..(24)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (29)..(29)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (34)..(34)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (39)..(39)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (44)..(44)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (49)..(49)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (54)..(54)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (59)..(59)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (64)..(64)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (69)..(69)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (74)..(74)
<223>  valine or cysteine present in a ratio of 1:1

<220>
<221>  X
<222>  (79)..(79)
<223>  valine or cysteine present in a ratio of 1:1

<400>  7

Val Pro Gly Xaa Gly Val Pro Gly Xaa Gly Val Pro Gly Xaa Gly Val 
1               5                   10                  15      


Pro Gly Xaa Gly Val Pro Gly Xaa Gly Val Pro Gly Xaa Gly Val Pro 
            20                  25                  30          


Gly Xaa Gly Val Pro Gly Xaa Gly Val Pro Gly Xaa Gly Val Pro Gly 
        35                  40                  45              


Xaa Gly Val Pro Gly Xaa Gly Val Pro Gly Xaa Gly Val Pro Gly Xaa 
    50                  55                  60                  


Gly Val Pro Gly Xaa Gly Val Pro Gly Xaa Gly Val Pro Gly Xaa Gly 
65                  70                  75                  80  


<210>  8
<211>  16
<212>  PRT
<213>  "AEBMP", polypeptide

<400>  8

Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser Leu Pro Glu Thr 
1               5                   10                  15      


